<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22112">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818972</url>
  </required_header>
  <id_info>
    <org_study_id>IP-0015-16</org_study_id>
    <nct_id>NCT02818972</nct_id>
  </id_info>
  <brief_title>Relay PRO Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers</brief_title>
  <official_title>A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the Relay PRO Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bolton Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bolton Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety and effectiveness of the Relay PRO Thoracic Stent-Grafts in subjects
      with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the
      descending thoracic aorta.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to investigate the safety and effectiveness of the Relay PRO
      Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms and penetrating
      atherosclerotic ulcers of the descending thoracic aorta.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Major Adverse Events (MAEs)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Aortic Aneurysm, Thoracic</condition>
  <arm_group>
    <arm_group_label>Relay Pro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovascular treatment with the investigational device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Relay PRO</intervention_name>
    <description>Endovascular treatment with investigational device.</description>
    <arm_group_label>Relay Pro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be â‰¥ 18 years of age

          -  Subject has specified disease in his/her descending thoracic aorta.

          -  Subject have anatomical compliance for the device specified for both access vessels
             and treatment area.

          -  Subject must be willing to comply with the follow-up evaluation schedule.

          -  Subject (or Legally Authorized Representative) agrees an Informed Consent Form prior
             to treatment.

        Exclusion Criteria:

          -  Subject has specified disease of the thoracic aorta which is not included in the
             trial, for example: aortic dissection, intramural hematoma, traumatic injury or
             transection, aortic false aneurysm, ruptured aneurysm.

          -  Subject anatomy with significant stenosis, calcification, thrombus or tortuosity.

          -  Subjects with specified compromised circulation.

          -  Subjects with specified prior procedures.

          -  Subjects with allergy to contrast media or device components.

          -  Subjects with disease, for example: suspected connective tissue disorder, specified
             coagulation disorders, specified coronary artery disease, severe congestive heart
             failure, stroke and/or Myocardial Infarction (MI) as specified, specified pulmonary
             disease, specified renal failure.

          -  Subjects that are pregnant or planning to become pregnant during the course of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 29, 2016</lastchanged_date>
  <firstreceived_date>June 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
